Varian Medical (NYSE:VAR) yesterday said it agreed to pay nearly $1.3 billion for Australia’s Sirtex Medical (ASX:SRX) and its anti-cancer microspheres.
The A$28-per-share offer, which values Sirtex at A$1.59 billion (about $1.28 billion), is slated to close in late May, Palo Alto, Calif.-based Varian said. It’s part of a bid to broaden that company’s oncology portfolio.
Get the full story at our sister site, Drug Delivery Business News.
The post Varian Medical to pay $1.3B for Sirtex appeared first on MassDevice.
from MassDevice http://ift.tt/2DWWsL0
Cap comentari:
Publica un comentari a l'entrada